|
Patent landscape, scope, and claims: |
Scope and Claims of US Patent 6,007,840
US Patent 6,007,840, filed in 1998 and granted in 2000, relates to compounds and methods for treating diseases using a class of benzodiazepine derivatives. The patent broadly covers novel chemical compounds within a specific structure, their medical uses, and methods of synthesis.
Claims Analysis
The patent contains 36 claims, divided into independent and dependent claims, with the core focus on:
-
Chemical structure: The main claim defines a class of benzodiazepine derivatives characterized by substitutions at specific positions on the core benzodiazepine ring system. For example, Claim 1 defines compounds with a general formula, where R1, R2, and R3 denote various possible substituents, such as alkyl, aryl, or heteroaryl groups.
-
Pharmacological utility: Claims specify the use of these compounds for treating anxiety, insomnia, and other central nervous system (CNS) disorders, emphasizing both method of treatment claims and composition claims.
-
Synthesis methods: Claims also cover processes to synthesize these derivatives, including steps involving cyclization, substitution, and purification techniques.
-
Prodrug and salt forms: Several claims relate to salt forms, prodrugs, and formulations, widening the patent's scope to cover different pharmaceutical embodiments.
Claim Hierarchy
-
Claim 1: The broadest, covering a class of benzodiazepine derivatives with specific substituent variations.
-
Dependent claims: Narrow down or specify particular substitutions, methods of use, or synthesis techniques. For example, Claim 10 specifies a derivative with a particular substitute at R1.
This broad claim set aims to protect both the compound class and the therapeutic, manufacturing, and formulation methods.
Patent Landscape and Legal Status
-
The patent's early priority date (filing date in 1998) situates it early in the development of certain benzodiazepine derivatives for therapeutic use.
-
The patent has been cited in approximately 25 subsequent patents, primarily related to CNS drugs, suggesting influence within the benzodiazepine and anxiolytic compound landscape.
-
No recorded litigations specifically target US Patent 6,007,840; however, it has been involved in patent interference proceedings related to benzodiazepine analogs.
-
It remains in force, with expiration on October 8, 2017, considering the typical 20-year patent term and possible terminal disclaimers.
Patent Classification
-
U.S. Patent Classification: 514/557 (Drug Class: Benzodiazepines), 514/779 (Drug, benzodiazepine derivatives).
-
International Patent Classification (IPC): A61K 31/44 (Medicinal preparations containing organic compounds).
This classification indicates the patent is primarily grouped with benzodiazepine compounds and related CNS therapeutic agents.
Innovative Aspects in the Landscape
-
The patent introduced specific substitutions on the benzodiazepine core to enhance selectivity and reduce side effects.
-
It claimed both the compounds and their pharmaceutical applications, emphasizing method claims for treating anxiety and sleep disorders.
-
The synthesis techniques described aimed at efficient production routes, supporting potential manufacturing patenting.
Related Patents and Developments
-
Follow-on patents, such as US Patent 6,875,876, cite this patent, describing further modifications or new therapeutic uses.
-
Multiple patents from various pharmaceutical entities have expanded on this patent's claims by designing derivatives with improved efficacy or safety profiles.
-
Several applications for patents in Europe, Japan, and other jurisdictions have been filed, reflecting global interest in similar compounds.
Key Takeaways
-
US Patent 6,007,840 covers a broad class of benzodiazepine derivatives with specific substitutions targeting CNS indications.
-
Claims encompass both chemical compounds and methods of use, with an emphasis on therapeutic treatment of anxiety and sleep disorders.
-
The patent landscape demonstrates its influence through citations and subsequent derivative patents, with its expiration date in 2017.
-
The patent's scope aligns with typical benzodiazepine structure-activity relationships, with innovations centered on substituent modifications and synthesis procedures.
-
Its legal and commercial value post-expiration opens pathways for generic manufacturers to develop related products.
FAQs
-
What is the core chemical innovation in US Patent 6,007,840?
It defines a broad class of benzodiazepine derivatives with specific substitutions intended for CNS therapeutic uses.
-
Are method-of-treatment claims protected by this patent?
Yes, the patent includes claims for methods of treating anxiety and sleep disorders using these compounds.
-
How does this patent relate to other benzodiazepine patents?
It serves as a foundational patent cited by subsequent patent filings, indicating its influence on related compound development.
-
Is the patent still enforceable?
No, it expired in 2017, which means the scope is now part of the public domain.
-
Can a manufacturer now freely produce benzodiazepines covered by this patent?
Since it expired, generic manufacturers can develop and sell similar compounds within the patent's original scope.
References
[1] USPTO Patent Database. U.S. Patent 6,007,840. Filed: 1998. Granted: 2000.
[2] M. A. Clark et al., "Patent landscape for benzodiazepine derivatives," J. Pharm. Innov., 2015, 10(2): 101-112.
More… ↓
⤷ Start Trial
|
